NICE's yes for multiple myeloma treatments follows final no for Bayer's Nexavar
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, issued on 2 June a preliminary recommendation for Celgene's Thalidomide Celgene (thalidomide) and Janssen-Cilag's Velcade (bortezomib) for multiple myeloma.